Your browser doesn't support javascript.
loading
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
Schumacher, Fredrick R; Al Olama, Ali Amin; Berndt, Sonja I; Benlloch, Sara; Ahmed, Mahbubl; Saunders, Edward J; Dadaev, Tokhir; Leongamornlert, Daniel; Anokian, Ezequiel; Cieza-Borrella, Clara; Goh, Chee; Brook, Mark N; Sheng, Xin; Fachal, Laura; Dennis, Joe; Tyrer, Jonathan; Muir, Kenneth; Lophatananon, Artitaya; Stevens, Victoria L; Gapstur, Susan M; Carter, Brian D; Tangen, Catherine M; Goodman, Phyllis J; Thompson, Ian M; Batra, Jyotsna; Chambers, Suzanne; Moya, Leire; Clements, Judith; Horvath, Lisa; Tilley, Wayne; Risbridger, Gail P; Gronberg, Henrik; Aly, Markus; Nordström, Tobias; Pharoah, Paul; Pashayan, Nora; Schleutker, Johanna; Tammela, Teuvo L J; Sipeky, Csilla; Auvinen, Anssi; Albanes, Demetrius; Weinstein, Stephanie; Wolk, Alicja; Håkansson, Niclas; West, Catharine M L; Dunning, Alison M; Burnet, Neil; Mucci, Lorelei A; Giovannucci, Edward; Andriole, Gerald L.
Afiliação
  • Schumacher FR; Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA. frs2@case.edu.
  • Al Olama AA; Seidman Cancer Center, University Hospitals, Cleveland, OH, USA. frs2@case.edu.
  • Berndt SI; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK. aa461@medschl.cam.ac.uk.
  • Benlloch S; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. aa461@medschl.cam.ac.uk.
  • Ahmed M; Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA.
  • Saunders EJ; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
  • Dadaev T; Institute of Cancer Research, London, UK.
  • Leongamornlert D; Institute of Cancer Research, London, UK.
  • Anokian E; Institute of Cancer Research, London, UK.
  • Cieza-Borrella C; Institute of Cancer Research, London, UK.
  • Goh C; Institute of Cancer Research, London, UK.
  • Brook MN; Institute of Cancer Research, London, UK.
  • Sheng X; Institute of Cancer Research, London, UK.
  • Fachal L; Institute of Cancer Research, London, UK.
  • Dennis J; Institute of Cancer Research, London, UK.
  • Tyrer J; Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Muir K; Fundación Pública Galega de Medicina Xenómica-SERGAS, Grupo de Medicina Xenómica, CIBERER, IDIS, Santiago de Compostela, Spain.
  • Lophatananon A; Department of Oncology, Centre for Cancer Genetic Epidemiology, Strangeways Laboratory, University of Cambridge, Cambridge, UK.
  • Stevens VL; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
  • Gapstur SM; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
  • Carter BD; Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester, UK.
  • Tangen CM; Warwick Medical School, University of Warwick, Coventry, UK.
  • Goodman PJ; Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester, UK.
  • Thompson IM; Warwick Medical School, University of Warwick, Coventry, UK.
  • Batra J; Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA.
  • Chambers S; Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA.
  • Moya L; Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA.
  • Clements J; SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Horvath L; SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Tilley W; CHRISTUS Santa Rosa Hospital-Medical Center, San Antonio, TX, USA.
  • Risbridger GP; Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.
  • Gronberg H; Australian Prostate Cancer Research Centre-Qld, Translational Research Institute, Brisbane, Queensland, Australia.
  • Aly M; Menzies Health Institute of Queensland, Griffith University, Nathan, Queensland, Australia.
  • Nordström T; Cancer Council Queensland, Fortitude Valley, Queensland, Australia.
  • Pharoah P; Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.
  • Pashayan N; Australian Prostate Cancer Research Centre-Qld, Translational Research Institute, Brisbane, Queensland, Australia.
  • Schleutker J; Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.
  • Tammela TLJ; Australian Prostate Cancer Research Centre-Qld, Translational Research Institute, Brisbane, Queensland, Australia.
  • Sipeky C; Chris O'Brien Lifehouse (COBLH), Camperdown, New South Wales, Australia.
  • Auvinen A; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • Albanes D; Dame Roma Mitchell Cancer Research Centre, University of Adelaide, Adelaide, South Australia, Australia.
  • Weinstein S; Monash Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Program, Department of Anatomy and Developmental Biology, Monash University, Victoria, Australia.
  • Wolk A; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Håkansson N; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • West CML; Department of Urology, Karolinska University Hospital, Stockholm, Sweden.
  • Dunning AM; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  • Burnet N; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Mucci LA; Department of Clinical Sciences at Danderyds Hospital, Karolinska Institutet, Stockholm, Sweden.
  • Giovannucci E; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
  • Andriole GL; Department of Oncology, Centre for Cancer Genetic Epidemiology, Strangeways Laboratory, University of Cambridge, Cambridge, UK.
Nat Genet ; 50(7): 928-936, 2018 07.
Article em En | MEDLINE | ID: mdl-29892016
Genome-wide association studies (GWAS) and fine-mapping efforts to date have identified more than 100 prostate cancer (PrCa)-susceptibility loci. We meta-analyzed genotype data from a custom high-density array of 46,939 PrCa cases and 27,910 controls of European ancestry with previously genotyped data of 32,255 PrCa cases and 33,202 controls of European ancestry. Our analysis identified 62 novel loci associated (P < 5.0 × 10-8) with PrCa and one locus significantly associated with early-onset PrCa (≤55 years). Our findings include missense variants rs1800057 (odds ratio (OR) = 1.16; P = 8.2 × 10-9; G>C, p.Pro1054Arg) in ATM and rs2066827 (OR = 1.06; P = 2.3 × 10-9; T>G, p.Val109Gly) in CDKN1B. The combination of all loci captured 28.4% of the PrCa familial relative risk, and a polygenic risk score conferred an elevated PrCa risk for men in the ninetieth to ninety-ninth percentiles (relative risk = 2.69; 95% confidence interval (CI): 2.55-2.82) and first percentile (relative risk = 5.71; 95% CI: 5.04-6.48) risk stratum compared with the population average. These findings improve risk prediction, enhance fine-mapping, and provide insight into the underlying biology of PrCa1.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article